Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957338 | 1.00 | CYP2D6 (0.47) | CYP2D6CYP3A4CYP2C19CYP1A2ENPP3 | |
| SCHEMBL21987454 | 0.91 | CYP2D6 (0.47) | CYP2D6CYP3A4CYP2C19CYP1A2ENPP3 | |
| SCHEMBL17362258 | 0.89 | CYP2D6 (0.45) | CYP2D6CYP3A4CYP2C19CYP1A2ENPP3 | |
| SCHEMBL16126799 | 0.88 | CYP2D6 (0.52) | CYP2D6CYP3A4CYP2C19CYP1A2ENPP3 | |
| SCHEMBL21987475 | 0.88 | CYP2D6 (0.52) | CYP2D6CYP3A4CYP2C19CYP1A2ENPP3 | |
| SCHEMBL25544479 | 0.85 | CYP2D6 (0.50) | CYP2D6CYP3A4CYP2C19CYP1A2ENPP3 | |
| SCHEMBL401343 | 0.85 | CYP2D6 (0.50) | CYP2D6CYP3A4CYP2C19CYP1A2ENPP3 | |
| SCHEMBL401342 | 0.85 | CYP2D6 (0.50) | CYP2D6CYP3A4CYP2C19CYP1A2ENPP3 | |
| SCHEMBL21801241 | 0.84 | ALDH1A1 (0.36) | CYP2D6CYP3A4CYP2C19ENPP3ENPP1 | |
| SCHEMBL21801242 | 0.84 | ALDH1A1 (0.36) | CYP2D6CYP3A4CYP2C19ENPP3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-7507742-B2 | Spirocyclic derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-7507742-B2 | Spirocyclic derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PFIZER, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PFIZER, INC. | 2007-06-07 | — | — | US | disclosed |
| WO-2007063391-A2 | SPIROCYCLIC QUINAZOLINE DERIVATIVES AS PDE7 INHIBITORS | PFIZER LIMITED (GB) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PDE7A, PDE7B, PDE3A | CYP2D6 52/4885CYP3A4 442/4885CYP2C19 140/4885 |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | CYP2D6 334/4885CYP3A4 215/4885CYP2C19 689/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | CYP2D6 28/4885CYP3A4 42/4885CYP2C19 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.